Can pregnant women take acotinib?

Acalabrutinib is a targeted therapy drug used to treat specific types of leukemia and lymphoma. It is a BTK inhibitor. However, there is currently a lack of sufficient clinical research data and relevant safety assessments on whether acotinib can be used safely by pregnant women, so its use by pregnant women is generally not recommended.

Since the mechanism of action of acotinib is to interfere with the growth and proliferation of leukemia and lymphoma cells by inhibiting BTK in the B cell receptor signaling pathway, its safety and impact on the fetus are unclear. Use of acotinib during pregnancy may result in potential risks to the fetus, including developmental abnormalities, fetal malformations, or other adverse effects. Therefore, during pregnancy, especially in early pregnancy, the use of acotinib or other drugs that have not been fully evaluated for safety should be avoided.

If a pregnant woman is diagnosed with leukemia or lymphoma during pregnancy, she should inform her doctor immediately and work with her doctor to discuss the most appropriate treatment plan. In this case, the doctor may conduct a comprehensive assessment of the patient's condition and the health of the pregnant woman, and weigh the risks and benefits of treatment to develop a personalized treatment plan. In some cases, doctors may recommend suspending acotinib treatment until the woman has given birth.

In general, pregnant women should try to avoid using acotinib or other drugs without adequate safety evaluation during pregnancy to reduce potential risks to the fetus. Pregnant women who suspect that they may be pregnant or discover that they are pregnant during pregnancy should inform their doctor immediately to obtain professional advice and guidance.